Revium Rx RVRC
OTC RVRC
$1.43 +0.00 (+0.00%)
At close: Sep 3, 2026 · 4:00 PM EDT

Revium Rx (RVRC) Consolidated Net Income (2025 - 2026)

Revium Rx's (RVRC) quarterly Consolidated Net Income came in at -$732000.0 in Q2 2026, up 21.96% year-over-year from -$600188.8 in Q2 2025, and up 21.96% quarter-over-quarter from -$938000.0 in Q2 2025.

Analysis

Revium Rx (RVRC) Consolidated Net Income (2025 - 2026) Analysis & Trends

Revium Rx has disclosed Consolidated Net Income across 2 years of filings, most recently posting -$732000.0 for Q2 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 601.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 164.49 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 97.50 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -13.27 Mn
10 Revium Rx 86.84 Mn 85.34 Mn - -732,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -732,000.00
Jun 30, 2025 -938,000.00